Description: Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders.
Home Page: www.aptinyx.com
APTX Technical Analysis
909 Davis Street
Evanston,
IL
60201
United States
Phone:
847 871 0377
Officers
| Name | Title |
|---|---|
| Dr. Norbert G. Riedel | Exec. Chairman |
| Dr. Andrew D. Kidd B.M. B.Ch., M.D. | CEO, Pres & Director |
| Mr. Ashish Khanna | CFO & Chief Bus. Officer |
| Mr. Patrick Flavin | Sr. Mang. of Corp. Devel. & Investor Relations |
| Ms. Molly Dir | VP of HR |
| Dr. Kathryn King Ph.D. | Sr. VP of Clinical & CMC Operations |
| Mr. Tim Noffke | VP of Program Management & Chief of Staff |
| Dr. Harald Murck M.D., Ph.D. | VP of Clinical & Medical Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3271 |
| Price-to-Sales TTM: | 45.3289 |
| IPO Date: | 2018-06-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |